Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
Company Overview
PROCEPT BioRobotics Corporation is a Silicon Valley-based surgical robotics company dedicated to transforming urologic patient care through innovative, minimally invasive solutions. With a deep commitment to clinical excellence, the company designs and manufactures advanced robotic systems that empower surgeons to perform precise procedures with predictable and reproducible outcomes.
Innovative Robotic Solutions
At its core, PROCEPT BioRobotics develops the AquaBeam and HYDROS Robotic Systems. These state-of-the-art platforms utilize real-time ultrasound imaging and advanced imaging guidance to enable personalized treatment planning. The AquaBeam system, the world’s first autonomous robotic platform for aquablation therapy, safely removes prostate tissue in cases of benign prostatic hyperplasia (BPH), regardless of anatomical variations or surgeon experience. The HYDROS system further integrates AI capabilities to optimize surgical planning and execution, improving both efficiency and clinical outcomes in urologic procedures.
Clinical Excellence and Evidence
The company’s approach is underscored by a robust body of clinical data, with over 150 peer-reviewed publications and multiple clinical trials validating the safety and efficacy of aquablation therapy. Surgeons benefit from a technology that delivers fast, consistent, and reproducible results. The focus on minimally invasive techniques is designed not only to reduce recovery time and complications but also to preserve critical functions such as sexual function and continence, thereby enhancing overall patient quality of life.
Advanced Technology and Real-Time Imaging
Through its image-guided surgical systems, PROCEPT BioRobotics provides surgeons with a multidimensional view of the prostate, allowing for precise tissue resection. The real-time ultrasound imaging incorporated into the robotic platforms ensures that each procedure is tailored to the unique anatomical characteristics of each patient. This level of personalization in treatment planning is crucial for achieving optimal clinical outcomes, demonstrating the company’s expertise in merging robotics, imaging technology, and surgical precision.
Market Position and Competitive Landscape
Operating within the highly specialized field of urologic surgical robotics, PROCEPT BioRobotics holds a distinctive position by focusing on treatments for BPH, a prevalent condition affecting millions of men in the United States. By pioneering aquablation therapy, the company has established itself as a credible innovator in an industry that demands rigorous clinical validation and continuous technological advancement. The combination of advanced robotics and a significant repository of clinical evidence sets the company apart from other medical device manufacturers, ensuring that its solutions remain relevant and trustworthy to both healthcare professionals and the broader medical community.
Operational Footprint and Product Strategy
While a majority of its revenue is generated in the United States, the company’s impact is increasingly global. PROCEPT BioRobotics is committed to expanding market access through strategic installations and consistent performance improvements across its product lines. With products that are designed to work effectively regardless of prostate size or shape, the company addresses a wide spectrum of patient profiles, enhancing its appeal within the diverse and competitive landscape of medical devices.
Commitment to Innovation and Quality
Innovation is central to the company’s ethos. Combining cutting-edge robotics with artificial intelligence, PROCEPT BioRobotics continually evolves its product offerings to meet the rigorous demands of modern urologic surgery. The operational philosophy emphasizes safety, efficiency, and clinical accuracy, ensuring that each robotic system not only meets but exceeds the necessary standards for transformational patient care. The company’s notable emphasis on clinical research and validation further reinforces its role as an authoritative and trusted player in the surgical robotics arena.
Summary
In summary, PROCEPT BioRobotics Corporation is a trailblazer in the field of surgical robotics, specializing in transformative solutions for urologic conditions such as BPH. By marrying innovative robotic technology with extensive clinical evidence, the company has redefined the parameters of minimally invasive surgery. Its dedication to advancing surgical precision and patient safety positions it as an essential contributor to modern urologic care. Investors and healthcare stakeholders seeking comprehensive insights into advanced medical device technologies will find this company’s approach both compelling and indicative of its expertise in the ever-evolving landscape of surgical robotics.
PROCEPT BioRobotics (NASDAQ: PRCT) announced results from the WATER III trial comparing Aquablation therapy to laser enucleation for treating large prostates (80-180mL). The international study, involving 186 men between December 2020 and September 2024, revealed that Aquablation therapy achieved similar symptom relief while demonstrating significantly better outcomes in key areas:
- Lower ejaculatory dysfunction rates (14.8% vs 77.1%)
- Lower stress incontinence rates (0% vs 9.1%)
- 0% procedural transfusion rate
The trial results, presented at the European Association of Urology 2025 Annual Congress in Madrid, add to Aquablation therapy's clinical foundation, which includes the WATER study, WATER II, and over 150 peer-reviewed publications.
PROCEPT BioRobotics (Nasdaq: PRCT) has announced two upcoming investor events in April 2025. The company will host an in-person investor event on April 25, 2025, from 8:00am to 9:30am PT at the Venetian Hotel in Las Vegas during the American Urological Association Annual Meeting.
The event will feature presentations from the company's management team, including the CEO, CFO, CCO, and CTO. Clinical perspectives will be provided by distinguished physicians from USC Urology, Endeavor Health, and Kansas City Urology Care.
Additionally, PROCEPT BioRobotics will report its Q1 2025 financial results on April 24, 2025, before market open, followed by a conference call at 8:00 a.m. ET. Both events will be accessible via webcast on the company's investor relations website, with recordings available for at least 90 days after the events.
PROCEPT BioRobotics (PRCT) reported strong Q4 2024 financial results with total revenue of $68.2 million, up 57% year-over-year. The company sold 60 new robotic systems in the US at an average price of $460,000. U.S. system revenue reached $27.6 million (+67%), while handpiece revenue grew to $29.3 million (+36%).
Full-year 2024 revenue was $224.5 million, representing 65% growth from 2023. The company achieved significant milestones including FDA 510(k) clearance for the HYDROS Robotic System and FDA-IDE approval for the WATER IV PCa prostate cancer study.
For 2025, PROCEPT projects revenue of approximately $320 million (+42% YoY) with an expected gross margin of 64.5%. Q4 2024 saw challenges with an acute saline shortage affecting 10-20% of Aquablation procedures.
PROCEPT BioRobotics (PRCT), a surgical robotics company specializing in urology solutions, has announced key upcoming events. The company will release its Q4 2024 financial results on February 25, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern Time.
Additionally, management will participate in two significant healthcare conferences: the TD Cowen 45th Annual Healthcare Conference on March 4, 2025, at 1:10 p.m. ET, and the 2025 Leerink Partners Healthcare Conference on March 11, 2025, at 3:00 p.m. ET. Live webcasts and archived recordings of all events will be available on the company's investor relations website for at least 90 days.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urological solutions, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The management team will deliver a presentation on Wednesday, December 4 at 8:30 a.m. Eastern Time.
The presentation will be accessible through a live webcast on the company's investor relations website. Interested parties can access the webcast recording for up to 90 days after the event through the company's website at https://ir.procept-biorobotics.com.
PROCEPT BioRobotics (NASDAQ: PRCT) has announced the pricing of its public offering of 1,923,076 shares of common stock at $91.00 per share, aiming to raise approximately $175 million in gross proceeds. A selling stockholder has granted underwriters a 30-day option to purchase up to an additional 288,461 shares. The offering, expected to close around October 31, 2024, is being managed by BofA Securities, Piper Sandler, and Morgan Stanley. The company will not receive proceeds from shares sold by the selling stockholder.
PROCEPT BioRobotics (NASDAQ: PRCT), a surgical robotics company specializing in urology solutions, has announced a $175 million public offering of common stock. A selling stockholder will grant underwriters a 30-day option to purchase up to an additional $26.25 million of shares. The company will not receive proceeds from the selling stockholder's share sale. BofA Securities, Piper Sandler and Morgan Stanley are acting as joint book-running managers. The offering will be conducted through a prospectus supplement and accompanying prospectus filed with the SEC.
PROCEPT BioRobotics reported strong Q3 2024 results with total revenue of $58.4 million, up 66% year-over-year. U.S. revenue grew 62% to $52.2 million, while international revenue increased 122% to $6.2 million. The company sold 45 robotic systems in the U.S. at an average price of $432,000. Gross margin reached a record 63.2%, up from 53.8% in the prior year. The company increased its 2024 guidance, projecting revenue of $222.5-223.0 million and improved its adjusted EBITDA loss forecast to $60.0 million. Cash position remained strong at $199.8 million as of September 30, 2024.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its plans to release third quarter 2024 financial results on October 28, 2024, before the market opens. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results.
Interested parties can access the call through a webcast link or a dial-in registration for sell-side research analysts. The live audio webcast and an archived recording will be available on the company's investor relations website. The webcast replay will be accessible for at least 90 days after the event.
PROCEPT BioRobotics (Nasdaq: PRCT) has received FDA approval to initiate a pivotal randomized clinical study for prostate cancer treatment. The WATER IV PCa trial will compare Aquablation therapy to radical prostatectomy in men with Grade Group 1 to 3 localized prostate cancer. This global multicenter study will enroll up to 280 patients across 50 centers, with a 10-year follow-up period.
The FDA has also granted Breakthrough Device Designation for Aquablation therapy in prostate cancer treatment. The study's co-primary endpoint focuses on morbidity at six months, with longer-term follow-up assessing treatment-related harm reduction and oncologic events. This trial could potentially revolutionize localized prostate cancer treatment for millions of men.
FAQ
What is the current stock price of Procept Biorobotics (PRCT)?
What is the market cap of Procept Biorobotics (PRCT)?
What is the primary focus of PROCEPT BioRobotics?
What are the key products offered by the company?
How does aquablation therapy work?
What role does clinical evidence play in the company’s reputation?
How does the HYDROS Robotic System differ from the AquaBeam system?
What distinguishes PROCEPT BioRobotics in the competitive landscape?
In which markets does PROCEPT BioRobotics operate?
How does the company improve surgical outcomes with its robotic systems?
